吉非替尼在非小细胞肺癌治疗中的研究进展

被引：26

作者：

卢宝安 ^{[1
]}

张新伟 ^{[2
]}

任秀宝 ^{[2
]}

机构：

[1] 天津市静海县医院胸外科

[2] 天津市肿瘤医院

来源：

中国肿瘤临床与康复 | 2010年 / 17卷 / 01期

关键词：

吉非替尼; 肺肿瘤/治疗学;

D O I：

10.13455/j.cnki.cjcor.2010.01.034

中图分类号：

R734.2 [肺肿瘤];

学科分类号：

100117 [系统生物医学];

摘要：

<正>肺癌是全球癌症导致死亡中最常见的病因,占整个肿瘤引起死亡的1/3。80%肺癌为非小细胞肺癌(NSCLC),而70%NSCLC确诊时已属晚期,难以通过手术或放疗进行根治性治疗。另外,超过50%的早期患者尽管经过手术、放疗以及辅助化疗等积极治疗后仍最终出现局部复发或远处转移。

引用

页码：78 / 81

页数：4

共 11 条

[1]

Breast cancer resistance protein (BCRP) affected acquired resistance to gefitinib in a "never-smoked" female patient with advanced non-small cell lung cancer [J].

Usuda, J. ;

Ohira, T. ;

Suga, Y. ;

Oikawa, T. ;

Ichinose, S. ;

Inoue, T. ;

Ohtani, K. ;

Maehara, S. ;

Imai, K. ;

Kubota, M. ;

Tsunoda, Y. ;

Tsutsui, H. ;

Furukawa, K. ;

Okunaka, T. ;

Sugimoto, Y. ;

Kato, H. .

LUNG CANCER, 2007, 58 (02) :296-299

[2]

Erlotinib response of EGFR- mutant gefitinib-resistant non-small-cell lung cancer.[J].John Wen-Cheng Chang;Chun-Liang Chou;Shiu-Feng Huang;Hung-Ming Wang;Jia-Juan Hsieh;Todd Hsu;Yun-Chung Cheung.Lung Cancer.2007, 3

[3]

Pooled analysis of the prospective trials of gefitinib monotherapy for EGFR-mutant non-small cell lung cancers [J].

Costa, Daniel B. ;

Kobayashi, Susumu ;

Tenen, Daniel G. ;

Huberman, Mark S. .

LUNG CANCER, 2007, 58 (01) :95-103

[4]

Epidermal growth factor receptor mutations and their correlation with gefitinib therapy in patients with non-small cell lung cancer: A meta-analysis based on updated individual patient data from six medical centers in mainland China [J].

Wu, Yi-Long ;

Zhong, Wen-Zhao ;

Li, Long-Yun ;

Zhang, Xiao-Tong ;

Zhang, Li ;

Zhou, Cai-Cun ;

Liu, Wei ;

Jiang, Bin ;

Mu, Xin-Lin ;

Lin, Xa-Ying ;

Zhou, Qing ;

Xu, Chong-Rui ;

Wang, Zhen ;

Zhang, Guo-Chun ;

Mok, Tony .

JOURNAL OF THORACIC ONCOLOGY, 2007, 2 (05) :430-439

[5]

Phase II randomized study of daily gefitinib treatment alone or with vinorelbine every 2 weeks in patients with adenocarcinoma of the lung who failed at least 2 regimens of chemotherapy [J].

Chen, Yuh-Min ;

Liu, Jacqueline Ming ;

Chou, Teh-Ying ;

Perng, Reury-Perng ;

Tsai, Chun-Ming ;

Whang-Peng, Jacqueline .

CANCER, 2007, 109 (09) :1821-1828

[6]

Comparative analysis of epidermal growth factor receptor mutations and gene amplification as predictors of gefitinib efficacy in Japanese patients with nonsmall cell lung cancer [J].

Sone, Takashi ;

Kasahara, Kazuo ;

Kimura, Hideharu ;

Nishio, Kazuto ;

Mizuguchi, Masayuki ;

Nakatsumi, Yasuto ;

Shibata, Kazuhiko ;

Waseda, Yuko ;

Fujimura, Masaki ;

Nakao, Shinji .

CANCER, 2007, 109 (09) :1836-1844

[7]

Remarkable effect of gefitinib retreatment in a patient with nonsmall cell lung cancer who had a complete response to initial gefitinib [J].

Yoshimoto, Akihiro ;

Inuzuka, Kanako ;

Kita, Toshiyuki ;

Kawashima, Atsuhiro ;

Kasahara, Kazuo .

AMERICAN JOURNAL OF THE MEDICAL SCIENCES, 2007, 333 (04) :221-225

[8]

Prospective validation for prediction of gefitinib sensitivity by epidermal growth factor receptor gene mutation in patients with non-small cell lung cancer [J].

Yoshida, Kimihide ;

Yatabe, Yasushi ;

Park, Ji Young ;

Shimizu, Junichi ;

Horio, Yoshitsugu ;

Matsuo, Keitaro ;

Kosaka, Takayuki ;

Mitsudomi, Tetsuya ;

Hida, Toyoaki .

JOURNAL OF THORACIC ONCOLOGY, 2007, 2 (01) :22-28

[9]

Gefitinib (IRESSA) in patients of Asian origin with refractory advanced non-small cell lung cancer: Subset analysis from the ISEL study [J].

Chang, Alex ;

Parikh, Purvish ;

Thongprasert, Sumitra ;

Tan, Eng Huat ;

Perng, Reury- Perng ;

Ganzon, Domingo ;

Yang, Chih-Hsin ;

Tsao, Chao-Jung ;

Watkins, Claire ;

Botwood, Nick ;

Thatcher, Nick .

JOURNAL OF THORACIC ONCOLOGY, 2006, 1 (08) :847-855

[10]

A review of the benefit–risk profile of gefitinib in Asian patients with advanced non‐small‐cell lung cancer.[J].Keunchil Park;Koichi Goto.Current Medical Research and Opinion?.2006, 3

← 1 2 →